Background
The development and use of live attenuated oral poliovirus vaccine, has eliminated paralytic poliomyelitis as a public health concern in the industrialized world [1] [2] [3] . However, in the developing world, where an estimated 200,000 cases of paralytic poliomyelitis occur each year similar success has yet to be achieved [4, 5] . Most of these cases reported from tropical and subtropical regions, are attributed to poor hygiene status, inadequate sanitation facilities among other factors facilitating the transmission of wild polioviruses and other enteric pathogens to the community [6] .
In 1988 the World Health Organization (WHO) proposed mass immunization campaigns with the trivalent oral polio vaccine (TOPV) among children less than 5 years of age. TOPV, an effective vaccine against poliomyelitis, along with acute flaccid paralysis surveillance has restricted the incidence of polio to only a few countries. The Vaccine Vial Monitor (VVM) is a small patch of heat-sensitive material placed on the vaccine vial to register cumulative heat exposure. A direct relationship exists between the rate at which the VVM changes colour and ambient temperature. This in turn affects the potency of the oral polio vaccine. [7] Objectives To evaluate the status of the cold chain infrastructure in Kenya and to determine the total TOPV virus concentration of retrieved field samples.
Methods

Consent:
This research did not involve human subjects and hence did not require the use of individual informed consent. Sampling: A stratified multi-stage sampling strategy was used. Stage I involved sampling of facilities at each level. Stage II involved sampling temperature of equipment, power source and backup used to store the TOPV within each sampled facility in the stage I. Stage III involved sampling TOPV vials from equipment which was sampled for evaluation in Stage II. A sample of each batch contained in the facility was sampled. A total of 14 health centres were evaluated for this study. 
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continued on next page A total of 23 TOPV vial samples were collected, separated into individual serotypes generating 69 samples for the potency test.
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Vaccine potency test. Potency of oral polio vaccine was assessed using L20 B cell line and tested using Karber's formula. Neutralization was fi rst done on Vaccine samples to separate the viruses into individual serotypes. The samples were then subjected to titration to determine the individual titre of each virus contained in the vials. This was then compared to the Vaccine Vial Monitor stage of the vials
Results and Discussion
Equipment a) Temperature Fourteen cold chain storage facilities were evaluated for temperature. Training on handling and discarding expired vaccine A total of 14 facilities both distributing and vaccinating had their staff interviewed on handling expired vaccines.
Table 3: Staff Trained on Handling Expired Vaccine
Of the fourteen facilities only one (7.1%) had written guidelines on handling expired vaccines while the other 13 (92.9%) facilities had no guidelines.
Records on Vaccine Receipt and Deliveries
All 14 facilities (100%) that were distributing and vaccinating had records for vaccine receipt and deliveries.
Vaccine Vial Monitor (VVM) Stages
Twenty three oral poliovirus vaccine vials were evaluated for Vaccine Vial Monitor stages. 
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Vaccine Potency
This was done according to WHO potency testing standards. Vaccine contained in the trivalent poliovirus vaccine vials was neutralized using highly specifi c antisera to separate the serotypes to single serotypes (1, 2, & 3) .this study included vaccines at VVM stages I and II as used in routine immunization. Our study showed that the average potency of polio vaccine serotype1, serotype 2 and serotype 3 were as follows; On average the vaccine vials used in the study were potent with satisfactory VVM and mean serotype titre. We found that some OPV vials had dissatisfactory VVM stage. Vaccine potency was seen to be directly proportional to VVM stage of vaccine vials. Vaccine vials kept at temperatures below -18°C had a better VVM leading to a better potency status. Some OPV Samples which had lower titre of serotype 2 were contributed to by the temperature of the equipment they were stored at.
A study needs to be done on the average difference between the satisfactory and dissatisfactory vials.
